HIGHFDA DRUG

Quallent Pharmaceuticals Health LLC Recall Expands for Duloxetine Delayed-Release Capsules Over Imp-

Breckenridge Pharmaceutical recalls duloxetine delayed-release capsules due to CGMP deviations raising N-nitroso-duloxetine impurity above interim limit. The bottles were distributed to Arizona, Indiana and New Jersey. Consumers should stop using the product and contact their healthcare provider for guidance.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
August 8, 2025
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
August 8, 2025
Hazard Level
HIGH
Brands
DULOXETINE, Quallent Pharmaceuticals Health, Towa Pharmaceutical Europe
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
2 states
At-Risk Groups
GENERAL, PREGNANT

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
DULOXETINE, Quallent Pharmaceuticals Health, Towa Pharmaceutical Europe
Product type
Duloxetine Delayed-Release Capsules
Model numbers
Lot 240927C, Exp 04/30/2027
UPC codes
82009-029, 82009-030, 82009-032, 82009-031, 82009-029-05, 82009-030-10, 82009-032-10, 82009-031-30 +1 more
Sizes
1000 capsules/bottle
Sold at
Unknown
Where affected
AZ, NJ

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    August 8, 2025

  2. Reported by FDA DRUG

    September 17, 2025

  3. RecallRadar source check

    April 18, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

CGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Breckenridge Pharmaceutical, Inc. or your healthcare provider for guidance. Notification method: Letter

About This Product

Duloxetine delayed-release capsules are prescribed antidepressant medications used for treating major depressive disorder, generalized anxiety disorder, and other conditions.

Why This Is Dangerous

Manufacturing deviations led to a potentially harmful impurity, N-nitroso-duloxetine, above interim limits, which may pose health risks with prolonged exposure.

Industry Context

This recall is not described as part of a broader industry pattern in the provided data.

Real-World Impact

The recall affects 3,591 bottles distributed to three states, with guidance to stop use immediately and seek medical guidance.

Practical Guidance

How to identify if yours is affected

  1. Check NDC 82009-030-10 on the bottle.
  2. Inspect Lot 240927C.
  3. Verify expiration date 04/30/2027.

Where to find product info

FDA recall page for enforcement report D-0621-2025.

What timeline to expect

Recall remedies typically processed within weeks to months; expect notices by Breckenridge through official channels.

If the manufacturer is unresponsive

  • Escalate to FDA Consumer Complaint Hotline
  • File a report with state attorney general if needed

How to prevent similar issues

  • Ensure manufacturers follow CGMP, verify NDC codes before dispensing
  • Consult prescriber about alternatives if stopping medication
  • Stay updated with FDA recall notices

Documentation advice

Keep recall notices, bottle labels, lot numbers, and correspondence with Breckenridge for refunds or replacements

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Product: Duloxetine Delayed-Release Capsules, USP, 30 mg. Bottle size: 1,000 capsules. Rx Only. NDC: 82009-030-10. Manufacturer: Towa Pharmaceutical Europe S.L., Martorelles ( Barcelona ), Spain. Manufactured for: Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands. Quantity: 3,591 bottles. Lot: 240927C. Expiration: 04/30/2027. Distributed to: AZ, IN, NJ.

Reported Incidents

No specific injuries or incidents are described in the recall notice.

Key Facts

  • Distributed to AZ, IN, NJ
  • Manufacturer: Towa Pharmaceutical Europe S.L. (Spain) for Quallent Pharmaceuticals Health LLC

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANT
Injury Types
POISONINGLACERATIONOTHER

Product Details

Model Numbers
Lot 240927C
Exp 04/30/2027
UPC Codes
82009-029
82009-030
82009-032
+6 more
Affected States
AZ, NJ
Report Date
September 17, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
HIGH

Duloxetine Capsules Recalled Over High N-Nitroso Impurity Risk

Towa Pharmaceuticals recalled 3,397 bottles of Duloxetine Delayed-Release Capsules on November 24, 2025. The recall stems from CGMP deviations resulting in N-nitroso-duloxetine levels exceeding FDA limits. Consumers must stop using the product immediately.

DULOXETINE
CGMP Deviations;
Read more